uploads/2017/08/Analyst-recommendations-1.png

Analyst Recommendations for Regeneron Pharmaceuticals in August

By

Updated

Recent developments

In July 2017, the EMA’s (European Medicines Agency) Committee for Medicinal Products for Human Use recommended a positive opinion to the EC (European Commission) for the marketing authorization of Dupixent for the treatment of adult individuals with moderate-to-severe atopic dermatitis.

In August 2017, Regeneron Pharmaceuticals (REGN) announced that its Phase 3 NURSERY trial, which investigated suptavumab (REGN2222) for preventing medically attended RSV (respiratory syncytial virus) infections in infants, could not meet its primary endpoint. Regeneron Pharmaceuticals has plans to discontinue any further clinical development with suptavumab.

Article continues below advertisement

Analyst recommendations

Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.” Twelve analysts recommended a “hold,” and one analyst suggested a “strong sell.”

Around ~48.0% of analysts covering Regeneron Pharmaceuticals in August 2017 suggested some form of a “buy” rating. On August 26, 2017, Regeneron Pharmaceuticals had a consensus 12-month target price of $494.43, which represents a ~3.5% return on investment. The SPDR S&P 500 ETF (SPY) invests ~2.1% of its total portfolio holdings in Regeneron Pharmaceuticals. It also invests ~1.7% in Johnson & Johnson (JNJ), a peer of Regeneron in the rheumatology drugs market.

Peer ratings

Twenty-five analysts were analyzing Vertex Pharmaceuticals (VRTX) in August 2017. Nine of them recommended a “strong buy,” and 11 recommended a “buy.” Five analysts recommended a “hold,” and none of them recommended any form of a “sell.”

Around ~80.0% of the analysts analyzing Vertex Pharmaceuticals in August 2017 suggested some form of a “buy” rating. On August 26, 2017, Vertex Pharmaceuticals had a consensus 12-month target price of $178.09, which represents a ~16.2% return on investment.

Nine analysts were analyzing Exelixis (EXEL) in August 2017. Two analysts recommended a “strong buy,” and four recommended a “buy.” Three analysts recommended a “hold,” and none of them recommended any form of a “sell.”

Around ~67.0% of the analysts analyzing Exelixis in August 2017 suggested some form of a “buy” rating. On August 26, 2017, Exelixis had a consensus 12-month target price of $29.83, which represents a ~9.8% return on investment.

Advertisement

More From Market Realist